FDA OKs Shionogi antibiotic for cUTI

Under Priority Review status, the FDA approves Shionogi & Co.’s  (OTCPK:SGIOY) antibiotic cefiderocol, branded as Fetroja, for the treatment of adult patients with complicated urinary tract infections (cUTI), including kidney infections caused by susceptible Gram-negative bacteria, who have limited or no alternative treatment options.

Fetroja also received Qualified Infectious Disease Product designation which provides for an additional five years’ market exclusivity in the U.S.

https://seekingalpha.com/news/3519634-fda-oks-shionogi-antibiotic-cuti